瘢痕疙瘩的发病机制、临床特征及治疗进展综述
A Review on the Pathogenesis, Clinical Features, and Therapeutic Advances of Keloids
DOI: 10.12677/jcpm.2026.51040, PDF,   
作者: 包金丹:延边大学医学院,吉林 延吉;金升元*:延边大学附属医院整形烧伤科,吉林 延吉
关键词: 瘢痕疙瘩发病机制临床特征治疗进展成纤维细胞Keloid Pathogenesis Clinical Features Therapeutic Advances Fibroblasts
摘要: 瘢痕疙瘩(Keloids)是一种常见的皮肤纤维增生性疾病,表现为创伤后皮肤组织的过度修复反应,其发病机制复杂,涉及遗传易感性、慢性炎症、细胞外基质代谢紊乱及成纤维细胞异常活化等多种因素。近年来,随着分子生物学和免疫学研究的深入,瘢痕疙瘩的病理机制逐渐被揭示,但其确切病因仍不完全明确。临床上,瘢痕疙瘩表现为超出原始伤口边界的隆起性瘢痕,常伴有瘙痒、疼痛及功能障碍,严重影响患者的生活质量。目前,治疗方法包括手术切除、糖皮质激素注射、放射治疗、激光治疗及新型生物制剂等,但复发率高仍是临床面临的重大挑战。本文系统综述了瘢痕疙瘩的流行病学特征、分子机制、临床表现、诊断标准及最新治疗进展,旨在为临床实践和未来研究提供理论依据和方向。
Abstract: Keloids are a common fibroproliferative skin disorder characterized by an exaggerated wound-healing response following cutaneous injury. The pathogenesis of keloids is complex and involves multiple factors, including genetic predisposition, chronic inflammation, dysregulation of extracellular matrix metabolism, and aberrant activation of fibroblasts. In recent years, advances in molecular biology and immunology have gradually elucidated the underlying pathological mechanisms; however, the precise etiology remains incompletely understood. Clinically, keloids present as raised scars that extend beyond the boundaries of the original wound and are frequently accompanied by pruritus, pain, and functional impairment, significantly compromising patients’ quality of life. Current therapeutic modalities include surgical excision, intralesional corticosteroid injections, radiotherapy, laser therapy, and emerging biologic agents; nevertheless, high recurrence rates continue to pose a major clinical challenge. This review systematically summarizes the epidemiological features, molecular mechanisms, clinical manifestations, diagnostic criteria, and recent advances in the management of keloids, aiming to provide a theoretical foundation and future directions for clinical practice and research.
文章引用:包金丹, 金升元. 瘢痕疙瘩的发病机制、临床特征及治疗进展综述[J]. 临床个性化医学, 2026, 5(1): 272-279. https://doi.org/10.12677/jcpm.2026.51040

参考文献

[1] Chen, Z., Gao, Z., Xia, L., Wang, X., Lu, L. and Wu, X. (2021) Dysregulation of DPP4-CXCL12 Balance by TGF-β1/Smad Pathway Promotes CXCR4+ Inflammatory Cell Infiltration in Keloid Scars. Journal of Inflammation Research, 14, 4169-4180. [Google Scholar] [CrossRef] [PubMed]
[2] Li, Z., Zhang, C., Zhang, Q., Dong, Y., Sha, X., Jiang, M., et al. (2023) Identification of a Potential Bioinformatics-Based Biomarker in Keloids and Its Correlation with Immune Infiltration. European Journal of Medical Research, 28, Article No. 476. [Google Scholar] [CrossRef] [PubMed]
[3] Ponasenko, A.V., Tsepokina, A.V., Khutornaya, M.V., Sinitsky, M.Y. and Barbarash, O.L. (2022) IL18-Family Genes Polymorphism Is Associated with the Risk of Myocardial Infarction and IL18 Concentration in Patients with Coronary Artery Disease. Immunological Investigations, 51, 802-816. [Google Scholar] [CrossRef] [PubMed]
[4] Wang, Y., Chen, Y., Wu, J. and Shi, X. (2024) BMP1 Promotes Keloid by Inducing Fibroblast Inflammation and Fibrogenesis. Journal of Cellular Biochemistry, 125, e30609. [Google Scholar] [CrossRef] [PubMed]
[5] Kim, M., Mirsky, N., Spielman, A., Mathew, P., Yechieli, R., Tang, J.C., et al. (2022) Evaluating Symptomatic and Psychosocial Well-Being after Keloid Treatment with SCAR-Q. Aesthetic Surgery Journal, 42, NP416-NP422. [Google Scholar] [CrossRef] [PubMed]
[6] Song, H., Liu, T., Wang, W., Pang, H., Zhou, Z., Lv, Y., et al. (2019) Tension Enhances Cell Proliferation and Collagen Synthesis by Upregulating Expressions of Integrin αvβ3 in Human Keloid-Derived Mesenchymal Stem Cells. Life Sciences, 219, 272-282. [Google Scholar] [CrossRef] [PubMed]
[7] Zhang, G., Liu, Z., Li, Z. and Xu, Y. (2024) Future Directions about Keloid Scars Based on Pathogenesis and Therapies. Clinical, Cosmetic and Investigational Dermatology, 17, 2391-2408. [Google Scholar] [CrossRef] [PubMed]
[8] Wang, Y., Zheng, L., Zhang, L., Tai, Y., Lin, X. and Cai, Z. (2024) Roles of MMP-2 and MMP-9 and Their Associated Molecules in the Pathogenesis of Keloids: A Comprehensive Review. Frontiers in Pharmacology, 15, Article 1444653. [Google Scholar] [CrossRef] [PubMed]
[9] Bai, R., Hao, L., Zhou, G., Fu, Q., Zhang, P., Lin, P., et al. (2024) The Mechanism of TGF-β Mediating BRD4/STAT3 Signaling Pathway to Promote Fibroblast Proliferation and Thus Promote Keloid Progression. Heliyon, 10, e38188. [Google Scholar] [CrossRef] [PubMed]
[10] Shi, C.K., Zhao, Y.P., Ge, P., et al. (2019) Therapeutic Effect of Interleukin-10 in Keloid Fibroblasts by Suppression of TGF-β/Smad Pathway. European Review for Medical and Pharmacological Sciences, 23, 9085-9092.
[11] Pu, X., Cao, X., Liu, H., Huang, W., Zhang, L. and Jiang, T. (2023) Isorhamnetin Attenuates the Proliferation, Invasion, Migration and Fibrosis of Keloid Fibroblasts by Targeting S1PR1. Experimental and Therapeutic Medicine, 26, Article No. 310. [Google Scholar] [CrossRef] [PubMed]
[12] Li, Z., Liang, L., Li, K. and Yang, B. (2025) Scutellarin Attenuates Keloid Fibroblast Progression by Targeting EGFR/PI3K/AKT Signaling: An Integrated Network Pharmacology and in Vitro Experimental Study. Toxicology and Applied Pharmacology, 505, Article 117564. [Google Scholar] [CrossRef
[13] Liu, X., Wang, S., Wu, S., Hao, Q., Li, Y., Guo, Z., et al. (2018) Exosomes Secreted by Adipose-Derived Mesenchymal Stem Cells Regulate Type I Collagen Metabolism in Fibroblasts from Women with Stress Urinary Incontinence. Stem Cell Research & Therapy, 9, Article No. 159. [Google Scholar] [CrossRef] [PubMed]
[14] Hosseini, A., Kumar, S., Hedin, K. and Raeeszadeh-Sarmazdeh, M. (2023) Engineering Minimal Tissue Inhibitors of Metalloproteinase Targeting MMPs via Gene Shuffling and Yeast Surface Display. Protein Science, 32, e4795. [Google Scholar] [CrossRef] [PubMed]
[15] Li, Q., Cheng, F., Zhou, K., Fang, L., Wu, J., Xia, Q., et al. (2021) Increased Sensitivity to TNF‑α Promotes Keloid Fibroblast Hyperproliferation by Activating the NF‑κB, JNK and P38 MAPK Pathways. Experimental and Therapeutic Medicine, 21, Article No. 502. [Google Scholar] [CrossRef] [PubMed]
[16] Abdu Allah, A.M.K., Mohammed, K.I., Farag, A.G.A., Hagag, M.M., Essam, M. and Tayel, N.R. (2019) Interleukin-6 Serum Level and Gene Polymorphism in Keloid Patients. Cellular and Molecular Biology, 65, 43-48. [Google Scholar] [CrossRef
[17] Nangole, F.W., Ouyang, K., Anzala, O., Ogengo, J. and Agak, G.W. (2021) Multiple Cytokines Elevated in Patients with Keloids: Is It an Indication of Auto-Inflammatory Disease? Journal of Inflammation Research, 14, 2465-2470. [Google Scholar] [CrossRef] [PubMed]
[18] Jia, F., Zhao, Q., Shi, P., Liu, H. and Zhang, F. (2022) Dupilumab: Advances in the Off-Label Usage of IL4/IL13 Antagonist in Dermatoses. Dermatologic Therapy, 35, e15924. [Google Scholar] [CrossRef] [PubMed]
[19] D’Arcy, Q., Gharaee-Kermani, M., Zhilin-Roth, A. and Macoska, J.A. (2022) The IL-4/IL-13 Signaling Axis Promotes Prostatic Fibrosis. PLOS ONE, 17, e0275064. [Google Scholar] [CrossRef] [PubMed]
[20] Qin, H., Zhang, L., Li, M., Liu, Y., Sun, S., Nie, W., et al. (2022) EGR1/NOX4 Pathway Regulates Oxidative Stress and Further Facilitates Fibrosis Progression in Keloids Responses to TGF-β1. Journal of Dermatological Science, 108, 138-145. [Google Scholar] [CrossRef] [PubMed]
[21] Delaleu, J., Charvet, E. and Petit, A. (2023) Keloid Disease: Review with Clinical Atlas. Part I: Definitions, History, Epidemiology, Clinics and Diagnosis. Annales de Dermatologie et de Vénéréologie, 150, 3-15. [Google Scholar] [CrossRef] [PubMed]
[22] Tan, S., Khumalo, N. and Bayat, A. (2019) Understanding Keloid Pathobiology from a Quasi-Neoplastic Perspective: Less of a Scar and More of a Chronic Inflammatory Disease with Cancer-Like Tendencies. Frontiers in Immunology, 10, Article 1810. [Google Scholar] [CrossRef] [PubMed]
[23] Hellwege, J.N., Russell, S.B., Williams, S.M., Edwards, T.L. and Velez Edwards, D.R. (2018) Gene-Based Evaluation of Low-Frequency Variation and Genetically-Predicted Gene Expression Impacting Risk of Keloid Formation. Annals of Human Genetics, 82, 206-215. [Google Scholar] [CrossRef] [PubMed]
[24] Huang, Y., Xu, S., Wu, Y., Gu, Z., Dong, C., Zhang, L., et al. (2025) Coping Tendencies Play Partial Mediating Role between Social Support and Anxiety/Depression among Chinese Keloid Patients. Frontiers in Psychiatry, 16, Article 1543484. [Google Scholar] [CrossRef
[25] Li, S., Lei, J., Wang, Y.H., et al. (2022) Rare Giant Corneal Keloid Presenting 26 Years after Trauma: A Case Report. World Journal of Clinical Cases, 10, 9776-9782. [Google Scholar] [CrossRef] [PubMed]
[26] Limandjaja, G.C., Niessen, F.B., Scheper, R.J. and Gibbs, S. (2020) The Keloid Disorder: Heterogeneity, Histopathology, Mechanisms and Models. Frontiers in Cell and Developmental Biology, 8, Article 360. [Google Scholar] [CrossRef] [PubMed]
[27] Zhong, C., Shi, K., Li, P., Qiu, X., Wu, X., Chen, S., et al. (2024) Single-Cell Sequencing Analysis and Bulk-Seq Identify IGFBP6 and TNFAIP6 as Novel Differential Diagnosis Markers for Postburn Pathological Scarring. Burns, 50, Article 107255. [Google Scholar] [CrossRef] [PubMed]
[28] Mavilakandy, A.K., Vayalapra, S., Minty, I., Parekh, J.N., Charles, W.N. and Khajuria, A. (2024) Comparing Combination Triamcinolone Acetonide and 5-Fluorouracil with Monotherapy Triamcinolone Acetonide or 5-Fluorouracil in the Treatment of Hypertrophic Scars: A Systematic Review and Meta-Analysis. Plastic & Reconstructive Surgery, 153, 1318-1330. [Google Scholar] [CrossRef] [PubMed]
[29] Hietanen, K.E., Järvinen, T.A., Huhtala, H., et al. (2019) Treatment of Keloid Scars with Intralesional Triamcinolone and 5-Fluorouracil Injections—A Randomized Controlled Trial. Journal of Plastic, Reconstructive & Aesthetic Surgery, 72, 4-11. [Google Scholar] [CrossRef] [PubMed]
[30] Park, J. and Kim, Y.C. (2020) Topical Delivery of 5-Fluorouracil-Loaded Carboxymethyl Chitosan Nanoparticles Using Microneedles for Keloid Treatment. Drug Delivery and Translational Research, 11, 205-213. [Google Scholar] [CrossRef] [PubMed]
[31] Haji Mohammadi, A., Seirafianpour, F., Khosravi, M., Jafarzadeh, A., Neshastesaz Kashi, H., Baradaran, H., et al. (2025) A Systematic Review of Comparative Clinical Trials on the Efficacy, Safety, and Patient Satisfaction of Ablative and Non-Ablative Laser Therapies for Atrophic, Hypertrophic, and Keloid Scars. Lasers in Medical Science, 40, Article No. 280. [Google Scholar] [CrossRef] [PubMed]
[32] Scarcella, G., Pieri, L. and Fusco, I. (2022) Skin Fractional Scar Treatment with a New Carbon Dioxide Scanner: Histological and Clinical Evaluation. Photobiomodulation, Photomedicine, and Laser Surgery, 40, 424-432. [Google Scholar] [CrossRef] [PubMed]
[33] Zeng, Q., Wu, Q., Deng, L., Hong, L., Li, R. and Chen, A. (2024) Enhancement of Facial Rejuvenation through a Combination of 1565 Nm Non-Ablative Fractional Laser with 30% Supramolecular Salicylic Acid. Journal of Visualized Experiments, 211, e66336. [Google Scholar] [CrossRef] [PubMed]
[34] Santos-Alves, A., Franco-de Sá, C., Soares, P., Saraiva, D., Casalta-Lopes, J. and Horta, R. (2025) Using Adjuvant Radiotherapy for Keloid Scars: A Patient and Observer Assessment Study. Cirugía y Cirujanos (English Edition), 93, 413-418. [Google Scholar] [CrossRef
[35] Saleem, S., Neema Asghar, M.e., Umer, A., Ahmed, S., Adeel, M.U., Khan, H., et al. (2025) Comparing the Effect of Intralesional 5-Fluorouracil (5-FU) Alone versus Intralesional 5-FU Combined with Triamcinolone Acetonide for Keloid Treatment. Cureus, 17, e84635. [Google Scholar] [CrossRef] [PubMed]
[36] Zhu, H.Y., Bai, W.D., Li, C., et al. (2016) Knockdown of lncRNA-ATB Suppresses Autocrine Secretion of TGF-β2 by Targeting ZNF217 via miR-200c in Keloid Fibroblasts. Scientific Reports, 6, Article No. 24728. [Google Scholar] [CrossRef] [PubMed]
[37] Luk, K., Fakhoury, J. and Ozog, D. (2022) Nonresponse and Progression of Diffuse Keloids to Dupilumab Therapy. Journal of Drugs in Dermatology, 21, 197-199. [Google Scholar] [CrossRef] [PubMed]
[38] Liu, Z., Xian, L., Li, J., Zheng, S. and Xie, H. (2024) Single-Cell RNA Sequencing Analysis Reveals the Role of TXNDC5 in Keloid Formation. Cytojournal, 21, Article 40. [Google Scholar] [CrossRef] [PubMed]
[39] Tam, A., Leclair, P., Li, L.V., Yang, C.X., Li, X., Witzigmann, D., et al. (2021) FAM13A as Potential Therapeutic Target in Modulating TGF-β-Induced Airway Tissue Remodeling in COPD. American Journal of Physiology-Lung Cellular and Molecular Physiology, 321, L377-L391. [Google Scholar] [CrossRef] [PubMed]
[40] Frech, F.S., Hernandez, L., Urbonas, R., Zaken, G.A., Dreyfuss, I. and Nouri, K. (2023) Hypertrophic Scars and Keloids: Advances in Treatment and Review of Established Therapies. American Journal of Clinical Dermatology, 24, 225-245. [Google Scholar] [CrossRef] [PubMed]
[41] Renz, P., Hasan, S., Gresswell, S., Hajjar, R.T., Trombetta, M. and Fontanesi, J. (2018) Dose Effect in Adjuvant Radiation Therapy for the Treatment of Resected Keloids. International Journal of Radiation Oncology, Biology, Physics, 102, 149-154. [Google Scholar] [CrossRef] [PubMed]
[42] Zhan, Y., Tong, Y., Wu, X., Wang, Z. and Zhang, G. (2025) Association between Keloid and Mental Disorders: Perspective from Genetic Evidence. Annals of General Psychiatry, 24, Article No. 42. [Google Scholar] [CrossRef] [PubMed]
[43] Liu, S., Yang, H., Song, J., Zhang, Y., Abualhssain, A.T.H. and Yang, B. (2022) Keloid: Genetic Susceptibility and Contributions of Genetics and Epigenetics to Its Pathogenesis. Experimental Dermatology, 31, 1665-1675. [Google Scholar] [CrossRef] [PubMed]